Results of a meta-analysis of eligible trials comparing LMWH vs no LMWH in preventing future pregnancy loss in women with inherited thrombophilia
| . | Proportion with outcome in the treatment group . | Proportion with outcome in the control group . | RR . | 95% CI . | P . | I2, % . | ||
|---|---|---|---|---|---|---|---|---|
| % . | n/N . | % . | n/N . | |||||
| Primary outcome | ||||||||
| Livebirth rate | 84.5 | 201/238 | 64.9 | 159/245* | 0.81 | 0.55-1.19 | .28 | 91.9 |
| Livebirth rate (multicenter trials) | 83.5 | 132/158 | 82.4 | 136/165* | 1.04 | 0.93-1.16 | .52 | 12.9 |
| Prior late loss† | ||||||||
| Livebirth rate | 84.2 | 128/152 | 59.0 | 92/156 | 0.81 | 0.38-1.72 | .58 | 95.3 |
| Livebirth rate (multicenter trials) | 81.9 | 59/72 | 90.8 | 69/76 | 1.12 | 0.97-1.30 | .13 | 0.0 |
| Prior recurrent early loss‡ | ||||||||
| Livebirth rate§ | 86.5 | 32/37 | 86.2 | 25/29 | 0.97 | 0.80-1.19 | .79 | N/A |
| . | Proportion with outcome in the treatment group . | Proportion with outcome in the control group . | RR . | 95% CI . | P . | I2, % . | ||
|---|---|---|---|---|---|---|---|---|
| % . | n/N . | % . | n/N . | |||||
| Primary outcome | ||||||||
| Livebirth rate | 84.5 | 201/238 | 64.9 | 159/245* | 0.81 | 0.55-1.19 | .28 | 91.9 |
| Livebirth rate (multicenter trials) | 83.5 | 132/158 | 82.4 | 136/165* | 1.04 | 0.93-1.16 | .52 | 12.9 |
| Prior late loss† | ||||||||
| Livebirth rate | 84.2 | 128/152 | 59.0 | 92/156 | 0.81 | 0.38-1.72 | .58 | 95.3 |
| Livebirth rate (multicenter trials) | 81.9 | 59/72 | 90.8 | 69/76 | 1.12 | 0.97-1.30 | .13 | 0.0 |
| Prior recurrent early loss‡ | ||||||||
| Livebirth rate§ | 86.5 | 32/37 | 86.2 | 25/29 | 0.97 | 0.80-1.19 | .79 | N/A |
N/A, not applicable; n/N, number (n) with outcome/number (N) in treatment group.
One participant in the control group (aspirin alone) had a twin pregnancy with 1 livebirth and 1 stillbirth.
Late loss is defined as 1 loss ≥10 wk.
Recurrent early loss is defined as 2 losses <10 wk.
All trials included were multicenter trials.